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ABSTRACT
Mammalian Rap1, the most conserved telomere-interacting protein, beyond its role within nucleus for the
maintenance of telomeric functions, is also well known for its pleiotropic functions in various physiological
and pathological conditions associated with metabolism, inflammation and oxidative stress. For all these,
nowadays Rap1 is the subject of critical investigations aimed to unveil its molecular signaling pathways and
to scrutinize the applicability of its modulation as a promising therapeutic strategy with clinical relevance.
However, the underlying intimate mechanisms of Rap1 are not extensively studied, but any modulation of
this protein level has been associated with pathologies like inflammation, oxidative stress and deregulated
metabolism. This is considerably important in light of the recent discovery of Rap1 modulation in diseases
like cancer and cardiac metabolic disorders. In this review, we focus on both the telomeric and nontelomeric
functions of Rap1 and its modulation in various health risks, especially on the heart.
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Introduction
Identification and structure of mammalian Rap1
Telomeres are specialized protein-DNA complex located at the
terminal ends of chromosomes that ensure genomic stability and
integrity.1,2 In mammalian cells, the telomeric DNA is bound by
a specialized six protein subunits known as shelterin complex,
which includes telomeric repeat-binding factor 1 (TRF1), telo-
meric repeat-binding factor 2 (TRF2), protection of telomeres 1
(POT1), TRF1-interacting nuclear protein 2 (TIN2), TIN2- and
POT1-organizing protein (TPP1) and repressor-activator protein
1 (Rap1)2,3 (Fig. 1). The shelterin complex regulates the length
of the telomeres and prevents chromosomal rearrangements or
chromosomes fusing to each other which could lead to chromo-
somal breaks and recombination.2
The Rap1 subunit was first identified as a predominant telo-
mere-binding protein in the budding yeast Saccharomyces cerevi-
siae (scRap1),4 where it directly recognizes telomeric DNA
through the cooperation of its two internal tandem Myb-type
domains.5 Unlike the budding yeast scRap1, mammalian Rap1
associates with telomeres exclusively through its interaction with
TRF2.6 Human Rap1 was ascertained through a yeast two-hybrid
screen of HeLa cDNAs (human cervical cancer cell) with human
TRF2 as bait.6 This yields a 399 Amino acid protein (»47kDa)
that have significant sequence similarity (24%-25%) and three
conserved sequence motifs in common with scRap1, featuring a
domain of a breast cancer susceptibility protein that appears on
its C-terminus (BRCT) in N-terminus, one central Myb DNA-
binding motif and Rap1-specific protein-interaction domain
(RCT) at the C terminus,6 indicating that it is a human ortholog
of scRap1. Multiple protein- and DNA-interaction domains
within Rap1 architecture suggest that Rap1 can work as an adap-
tor protein, introducing different protein/DNA factors into the
shelterin complex with various functions.
Telomeric functions of Rap1
Rap1 and telomere length control
Because of the “end replication problem”, whereby the DNA
replication leaves 50–200 base pairs DNA un-replicated at the
3' end leading to shorter telomere ends at each cycle of cell divi-
sion, cumulative telomere attrition during ageing occurs in
eukaryotes.7 Thus, telomere length reflects the life span of a cell
and has been shown to be closely associated with several health
outcomes, including, but not limited to myocardial infarction,8
atherosclerosis9 and cancer.10
In budding yeast, scRap1 binds to telomeric DNA through
Myb domain and tethers Rif1 and Rif2 through protein interac-
tions within the RCT domain, thereby inhibiting the telomere
length elongation.11–13 The effect of Rap1 on telomere length
control in mammalian cells was believed to be evolutionarily
conserved. In human fibrosarcoma cell line HTC75, which has
been widely used as telomere length control test system,14 inhi-
bition of endogenous human Rap1 by RNA interference dis-
played a telomere elongation phenotype.15 It is likely that
BRCT and Myb domains within the Rap1 structure recruit one
or more protein factors, which together with endogenous Rap1
are required for the negative control of telomere length, as
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evidenced by higher telomere elongation rates in the four
mutants of Rap1 (Rap1DM, Rap1DBr, Rap1DBrDM, Rap1DMDCT)
than that in HTC75 cells overexpressing wild-type Rap1.16
However, recent studies challenged the role of mammalian
Rap1 in telomere length control.17,18 Loss of Rap1 in various
human cell lines [including Hela, HT1080, HTC116, ARPE-19]
through transcription activator-like effector nuclease (TALEN)
did not affect the telomere length dynamics, suggesting that
Rap1 does not play a significant role in telomere length con-
trol.17 Furthermore, Rap1 knockout mice are alive and fertile.18
Quantitative telomere fluorescence in situ hybridization analy-
sis of the liver and brown fat sections from both Rap1 wild-
type and knockout mice showed that there was no change in
telomere length between both genotypes.19 It is pointed out
that the prior finding of altered telomere length upon over
expression of Rap1 mutants could be due to the influence of
nucleoplasmic titration of factors on the phenotypes.17 It is
unclear why partial Rap1 inactivation by shRNA or TALEN-
mediated Rap1 knockout showed contrary findings. The role of
endogenous mammalian Rap1 in telomere length control still
requires further investigation.
Rap1 and telomere end protection
The central function of eukaryotic telomeres is to protect chro-
mosome ends from DNA degradation, unwanted DNA repair
mechanisms and chromosome fusions20 (Fig. 1). The shelterin
subunit TRF2 is life essential in telomere end protection since
the deletion of TRF2 from telomeres results in the Ataxia Tel-
angiectasia Mutated (ATM) kinase-dependent DNA damage
signaling and the non-homologous end-joining (NHEJ) path-
way-mediated massive end-to-end chromosome fusions.21,22
Furthermore, TRF2 also specifically inhibits homology-directed
repair (HDR), which can create different telomeric sister chro-
matid exchanges, leading to the shortened telomere in one
daughter cells.23
Mammalian Rap1, as an interacting partner of TRF2 in the
telomere, is also removed upon the deletion of TRF2.6,24 Thus,
Rap1 may contribute to the repression effect of TRF2 on ATM
signaling, NHEJ and HDR pathway at the telomere. However,
unlike TRF2¡/¡ cells, deletion of Rap1 (Rap1Dex2/Dex2) in
SV40LT-immortalized mouse embryonic fibroblasts (MEFs) did
not affect the expression level and localization of other shelterin
subunits and did not show ATM-dependent DNA damage
response, phosphorylation of Chk1 and Chk2 and induction of
Telomere Dysfunction-induced Foci (TIFs), which are hallmarks
of telomere dysfunction.18,25 Furthermore, in Rap1Dex2/Dex2 and
TRF2 knockout MEFs with TRF2 mutant (TRF2DRap1), that can-
not bind to Rap1 in the telomere but retained its interaction
with the TRF2-interacting protein Apollo,18 telomere fusions
were also not induced like wild-type TRF2 MEFs because of the
repressed NHEJ pathway mediated repair of telomeres.18,25 Col-
lectively, these data indicated that mammalian Rap1 is dispens-
able in either the repression of NHEJ or ATM kinase signaling.
In support of this notion, Rap1Dex2/Dex2 mice were born at the
expected frequencies and were fertile, suggesting that deletion of
Rap1 does not lead to lethal telomere dysfunction.18,25
In contrast with its role in ATM kinase signaling and NHEJ
pathway, Rap1 is critical to repress aberrant HDR at telo-
meres.18,25 Indeed, in MEFs lacking TRF2 and Ku70 which dis-
played frequent telomere sister chromatid exchanges (T-SCEs),
introduction of TRF2DRap1 did not down-regulate the level of
T-SCEs and failed to suppress the telomeric HDR, whereas
wild-type TRF2 significantly repressed the telomeric exchanges,
suggesting that mammalian Rap1 may contribute to the repres-
sion of HDR pathway at telomere.18,25 This observation is fur-
ther supported by Rap1 knockout studies, in which Cre-
mediated Rap1 knockout in Ku70 deficient MEFs exhibit signif-
icantly increased T-SCEs.18 Taken together, these data indicate
that mammalian Rap1 functions to repress HDR at the telo-
mere. Despite the mechanism by which Rap1 supresses HDR
pathway at telomeres remains largely unknown, the Rap1 Myb
motif has been suggested to be essential to cooperate with pri-
mary domain of TRF2 to repress the localization of poly(ADP-
ribose) polymerase 1 (PARP1) and SLX4 structure-specific
endonuclease subunit (SLX4) to telomeres, both proteins have
been demonstrated to be involved in HDR pathway.24,26 In sup-
port of this notion, a »35fold increase in PARP1 localization to
telomeres was observed in MEFs lacking Rap1-TRF2 hetero-
dimers.24 The murine SLX4 telomeric localization mainly
depends on the presence of functional PARP1, since inhibition
of PARP1 leads to »5fold reduction in SLX4 localization to
telomeres. This suggests that increased telomeric localization of
PARP1 and SLX4 in MEFs lacking Rap1-TRF2 heterodimers
promote the rapid telomere resection, and formation of telo-
mere-free chromosome ends.24 Thus, these findings collectively
Figure 1. Telomere structure and functions. Mammalian telomere consists of TTAGGG repeats and end with 30 G-strand overhang of up to a few nucleotides in length.
Shelterin complex is formed by TRF1 (telomere repeat-binding factor 1), TRF2, Rap1 (repressor activator protein 1), TIN2 (TRF1-interaction factor 2), POT1 (protection of
telomere 1) and TPP1 (POT1-organizing protein). Shelterin binds to double-stranded telomeric repeats and protects chromosome ends from ATM (ataxia telangiectasia
mutated)- dependent DNA damage signaling, c-NHEJ (classical non-homologous end joining)-induced DNA repair, homology-directed repair.
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demonstrated the biological importance of Rap1 in telomere
end protection by repressing the aberrant HDR pathway.
Nontelomeric functions of Rap1
Rap1 role in transcriptional control
In budding yeast, scRap1 can directly bind to specific sites on
DNA through its two Myb motif and function as a transcrip-
tional repressor or activator.27 This transcriptional effect of Rap1
is evolutionarily conserved in mammalian cells. Chromatin
immune precipitation (ChIP)-sequencing reveals that Rap1-con-
taining complex binds to both telomeric and extratelomeric
TTAGGG repeats.28 In line with this, preferential derepression
of subtelomeric genes which are enriched with Rap1-binding
sites was observed in Rap1-deficient MEFs, as compared to wild-
type cells.28 Furthermore, apart from the changes in subtelomeric
gene expression, there are at least 16 genes involved in cell adhe-
sion, cancer and metabolism, which were significantly upregu-
lated or downregulated in Rap1-deficient MEFs.28 However,
unlike scRap1, mammalian Rap1 cannot directly bind to telo-
meric DNA, since the surface of its Myb domain lacks positive
charge.29 Supporting this notion, electrophoretic mobility shift
assay studies have shown that Rap1 cannot bind to telomeric
DNA until the molar ratio of Rap1:DNA reaches up to 40:1.30 It
is, therefore, most likely that Rap1 exerts the transcriptional
effect via its interacting partner, TRF2. Indeed, human Rap1
induces a partial release of TRF2 from telomeric DNA and with
the higher concentration of Rap1, increasing amount of free
DNA was observed.30 Furthermore, there are »2fold increased
the selectivity of TRF2 binding to telomeric DNA in the presence
of Rap130. Taken together, these findings indicate that Rap1 may
play a role in the transcriptional control by modulating TRF2
attraction to telomeric and extratelomeric DNA.
Rap1 role in metabolism
Telomeric dysfunction and mitochondrial DNA damageare
characteristic features of cellular senescence and organismal
ageing, which are associated with age-related conditions like
diabetes and atherosclerosis.31,32 Furthermore, it is remarkable
that the function of the mitochondrial regulators (PGC-1a and
PGC-1b) declines across ageing tissues. The significance of
PGCs to insulin resistance and diabetes may stem from their
control of salutary metabolic pathways such as fatty acid
metabolism, gluconeogenesis and mitochondrial biogenesis.33,34
It is intriguing that, telomerase (TERT) depletion in mice
repressed the expression of PGC-1a results in reduced mito-
chondrial mass and function in liver and heart tissues,35 indi-
cating a relation between telomere dysfunction and
mitochondrial compromise in mammalian cells.
Since mammalian Rap1is involved in telomeric stability and
its regulation,16,36,37 it is anticipated that Rap1 may have regula-
tory control over metabolism through the telomere protection.
Indeed, the role of mammalian Rap1 on metabolism has been
characterized in both in vitroand in vivo system.19,28 Of particu-
lar interest, Rap1 knockout mice demonstrated reduced expres-
sion of PGC1a.19 However, it appears that mammalian Rap1
regulates metabolism independent of telomeric dysfunction
since there was no evident of telomeric attrition upon Rap1
depletion in mice.
In budding yeast, scRap1 controls metabolism through regu-
lation of enzymes and genes involved in glycolysis and ribo-
somal synthesis38 scRap1 participates in enhancer function of
multiple genes implicated in glycolysis by mapping with
upstream activation site elements (UAS) of glycolytic genes
such as phosphoglycerate kinase (PGK1),39 pyruvate kinase
(PYK1)40 and pyruvate decarboxylase (PDC1).41 Furthermore,
scRap1 can tether with GCR1 (CTTCC sequence motif) for
maximal Rap1 dependent glycolytic gene expression39,42 Thus,
Rap1 plays a passive role in the gene regulation of glycolytic
enzymes perhaps by allowing specific regulators to find their
DNA-binding sites.
Although nontelomeric activities of scRap1 have been thor-
oughly studied in yeast, the role of mammalian Rap1 in metab-
olism is commencing to reveal through experiments in Rap1
knockout mice. Martinez et al. reported that mammalian Rap1
regulates metabolism through transcriptional regulation of the
PPARa and PGC1a genes by binding to an intragenic F3
region in Ppara and Pgc1a loci.19 Furthermore, Rap1 defi-
ciency leads to decreased activation of PPARa and PGC1a and
eventually leading to deregulation of metabolic pathways
involved in energy homeostasis.19 Livers of Rap1 deficient mice
demonstrated reduced expressions of carnitine palmitoyl trans-
ferase (a rate-limiting step in fatty acid oxidation), phosphoenol
pyruvate carboxykinase (a key gluconeogenic enzyme) and sev-
eral fatty acid transporters (SLC27a2 and CD36).19 Deletion of
Rap1 in mice causes dysfunction of the liver as well as adipose
tissue, leading to excess fat accumulation, hepatic steatosis, glu-
cose intolerance and insulin resistance.19,43 An interesting
observation in this study is that Rap1 deficient mice exhibited
sexual dimorphism in age-dependent obesity i.e. more accentu-
ated in females, a similar feature observed with PPARa- and
PGC1a-deficient mice.44,45 Furthermore, Rap1-null MEFs
demonstrated significant down-regulation of metabolic genes,
particularly genes related to insulin secretion (FABP4,
PLA2G4A, ADCY8, MGLL, GDA, PYCR1, DPYD, PPAP2B)
and peroxisome-proliferator-activated receptor signaling (LPL,
UCP1, FABP4, ANGPTL4, PPARg, ACSL4, PCK2). Besides,
genes involved in type II diabetes (PIK3R5, CACNA1G,
PIK3R3, SLC2A4) were up-regulated in Rap1-null MEF.28
These results underscore a direct physiologic role of Rap1 in
regulation of metabolic signaling pathways and forging a link
between mammalian Rap1 and metabolism (Fig. 2).
Rap1 role in inflammation
Inflammation is considered as a physiological homeostatic
response of the organism to noxious stimuli. Inflammatory
milieu comprises the synchronized action of various kinds of
inflammatory mediators like cytokines, eicosanoids, chemo-
kines and products of proteolytic cascades.46 The nuclear factor
(NF)kB has long been recognized as “prototypical pro-inflam-
matory signaling pathway”, chiefly based on the role of NFkB
in the expression of cytokines, chemokines and adhesion mole-
cules.47 Genome-wide gain-of-function studies revealed that
Rap1 as an inhibitor kinase (IKK) adaptor that controls NFkB
activity in a dose-dependent manner.48–50 We and others
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demonstrated that cytoplasmic Rap1 is associated with NFkB
mediated inflammation in macrophages and various cancer cell
lines.48,51 Interestingly, cytoplasmic Rap1 in human cells does
not associate with TRF2,52 perhaps it is this fraction that cou-
ples with IKK complex.51 Cytoplasmic Rap1 has been associ-
ated with several inflammatory-related diseases like cancer,48
atherosclerosis,51 corneal alkali injury53, myocardial infarc-
tion54, and liver ischemia-reperfusion injury.55
The non-canonical inflammatory role of cytoplasmic Rap1
has been comprehensibly deciphered in breast cancer BT476
and epithelial cancer HeLa S3 cell lines.48 In these human can-
cer cell lines, cytoplasmic Rap1 binds to IKK, thereby promotes
subsequent degradation of inhibitor of kappa B (IkB) protein,56
which is the endogenous NFkB inhibitor.57 Thus, cytoplasmic
Rap1 by recruiting IKKs ensures efficient NFkB activation via
phosphorylation of p65 subunit.48 We further demonstrated
that cytoplasmic Rap1 plays a role in inflammation in macro-
phages.51 Rap1 deficiency in pro-inflammatory phenotypic
macrophages i.e. differentiated THP-1 cells and peritoneal
macrophages downregulated the expression of pro-inflamma-
tory cytokines (including interleukin (IL)-1a, monocyte che-
moattractant protein 1 (MCP-1), tumor necrosis factor (TNF)-
a) and enhanced IkBaexpression. In contrast, Rap1 deficiency
in anti-inflammatory macrophages (bone marrow derived M2
macrophages)are less uniform, as it up-regulated the expression
of IL-1a, IL-6,IkBa, while down-regulated MCP-1 expression.
Moreover, the induction of NFkB-mediated pro-inflammatory
cytokine production by Rap1 is restricted to macrophages as it
does not appear in human endothelial and smooth muscle cell
lines, which warrants further elucidation.51 Also, inhibition of
Rap1 promotes better corneal recovery following alkali injury
that was accompanied by inhibition of NFkB and reduced up-
regulation of cytokine (IL-1a) and finely regulated levels of
angiogenic factor (vascular endothelial growth factor) and anti-
angiogenic factor (pigment epithelium-derived factor).53 There-
fore, the presence of Rap1 facilitates the pro-inflammatory
environment by favoring the production of pro-inflammatory
cytokines and by limiting the anti-inflammatory cytokines
(Fig. 2).
We further observed persistent stimulation of NFkB with
either lipopolysaccharide or TNFa enhanced Rap1 levels, indicat-
ing the presence of a positive feedback loop for Rap1 self-activa-
tion in macrophages.51 A similar observation was reported in
murine embryonic fibroblast cells were abrogated NFkB stimula-
tion associated with diminished Rap1 expression.48 However,
more Rap1 levels were observed in the total cellular extracts,
when the p65 subunit was over-expressed.48 Indeed, the Rap1
promoter region comprises binding sites for NFkB.48 Persistent
stimulation of NFkB pathway in macrophages leading to aug-
mented secretion of cytokines has been associated with the devel-
opment and progression of atherosclerosis.58–60 The Rap1-NFkB
positive feedback loop could be a possible mechanism which
ensures chronic pro-inflammatory environment by constitutive
activation of NFkB activation throughout the atherosclerosis pro-
gression and development.61,62
Interestingly, Rap1 has a significant role in mesenchymal
stem cell (MSC) based therapy against myocardial infarction
via regulation of NFkB activity.54 Knockdown of Rap1 with
shRap1 led to decreased translocation of p65-NFkB from the
cytoplasm to nuclei following TNF-activation. Furthermore,
Figure 2. Nontelomeric functions of Rap1. Rap1 regulates various nontelomeric functions like metabolism, oxidative stress, and inflammation. Rap1controls energy
metabolism by increasing fatty acid oxidation via increasing the expression of carnitine palmitoyltransferase, and fatty acid transporters such as SLC27A2 and CD36 and
by increasing gluconeogenesis via increasing the expression of phosphoenolpyruvate carboxykinase. Rap1 also regulates mitochondrial biogenesis by increasing PGC-1a
expression. Furthermore, Rap1 upregulates metabolic genes related to insulin secretion (FABP4, PLA2G4A, ADCY8, MGLL, GDA, PYCR1, DPYD, PPAP2B) and peroxisome-
proliferator-activated receptor signaling (LPL, UCP1, FABP4, ANGPTL4, PPARg, ACSL4, PCK2). In inflammation, Rap1 stimulates NFkB activations and upregulates the
expression of proinflammatory cytokines such as IL-1a, MCP-1, TNF-a, and neutrophil adhesion molecules such as ICAM-1 and VCAM-1. Rap1 also modulates oxidative
stress by increasing the expression of NFkB and sirtuins.
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Rap1 knockout bone marrow-derived MSCs displayed a
markedly reduced ratio of phosphorylated NFkB to NFkB-p65
and Bax to Bcl-2, and enhanced tolerance to hypoxia-induced
apoptosis when compared to wild-type bone marrow-derived
MSCs.54 Moreover, deletion of Rap1 in bone marrow-derived
MSCs resulted in decreased activity of NFkB, escorted by
reduced pro-inflammatory paracrine cytokine mediators TNF-
a, IL-6 and MCP-1 compared with wild-type bone marrow-
derived MSCs.54 In contrast, re-introduction of Rap1 in Rap1
knockout bone marrow-derived MSCs resulted in the loss of
resistance to hypoxia-induced apoptotic death.54 These results
suggest that abolition of Rap1 boosts MSC survival capacity
under hypoxic conditions. Furthermore, in vivo transplantation
of Rap1 knockout bone marrow-derived MSC contributed
more to the recovery of heart function and had a better thera-
peutic efficacy than wild-type bone marrow-derived MSCs for
cardiac repair post myocardial infarction.54 In summary, Rap1
has a crucial role in facilitating MSC paracrine component and
MSC cell survival potential. Therefore, specific deletion of Rap1
in bone marrow-derived MSCs presents a novel approach to
boost prospective MSC-based therapy by controlling paracrine
profiling.
Similar to the above observation, Rap1 has been shown to be
involved in accelerating liver ischemia/reperfusion injury (IRI)
by elevating neutrophil inflammatory response.55 Overexpres-
sion of Rap1 was accompanied with severe neutrophil-medi-
ated hepatic inflammatory response and has been shown a
positive correlation with acute phase liver graft injury in both
human and rat liver transplantation. Furthermore, in mice
hepatic IRI model and primary neutrophils, knockout of Rap1
reduced liver damage and suppressed neutrophils migration
activity and adhesion molecules (intracellular adhesion mole-
cule-1 and vascular cell adhesion molecule-1) through decreas-
ing neutrophils F-Actin expression and chemokine (C-X-C
motif) ligand/receptor 2 (CXCL2/CXCR2) pathways.55 Besides,
knockout Rap1 alleviated mouse liver IRI not only through
suppressing migration of neutrophils but also through inhibit-
ing the neutrophils function through NFkB and mitogen-acti-
vated protein kinase signaling pathways.55 Thus, Rap1 can be
considered as a promising therapeutic target of attenuating
liver IRI and myocardial infarction.
Rap1 role in oxidative stress
Oxidative stress plays a crucial role in the progression of diabetes
and associated cardiomyopathy.63 Reactive oxygen species (ROS)
like hydroxyl free radical, superoxide anion and hydrogen perox-
ide could cause damage to lipids, proteins, and DNA.64 It is well
described that hyperglycemia provokes stimulation of ROS pro-
duction due to impaired function of mitochondrial electron
transport chain. ROS overproduction is the primary cause for
hyperglycemia-induced cell damage.65,66 It is well established that
oxidative stress and sirtuins are mutually linked together that
oxidative stress can alter the sirtuins functions at different levels
such as expression, posttranslational modifications, and protein-
protein interactions67 whereas sirtuins can control oxidative
stress by directly deacetylating several transcription factors that
regulate antioxidant genes like FOXO and p65-subunit of
NFkB.68–70 Furthermore, Rap1 association with sirtuins in yeast
was characterized.71,72 A study conducted in wine yeasts demon-
strated that ethanol-induced ROS and superoxide signals was
accompanied by increased proteins levels of sirtuins (Sir1,Sir2,
Sir3) and Rap1, that interacts with Sir complex,73 which suggests
that Rap1 modulates oxidative stress in yeast and is speculated
that can be conserved in mammals as well, though it warrants
further investigation.
A recent study showed a link between telomere length, oxi-
dative stress and the onset of diabetes.74 Telomere shortening
due to oxidative stress eventually leads to beta cells senescence
and the subsequent apoptosis which accelerates the inception
of diabetes.74 Since Rap1 exert a direct effect on telomere
homeostasis and regulation of telomere length, it is hypothe-
sized that Rap1 may respond to oxidative stress. Swanson et al.
observed that decrease in telomere length was associated with
reduced levels of TRF2 and Rap1 in aged human dermal fibro-
blasts.75 Interestingly, only nuclear levels but not the cyto-
plasmic pool of Rap1 were decreased significantly in two
different cell lines like human dermal fibroblasts (do not
express telomerase) and U251 glioblastoma cells (express telo-
merase) when exposed to hydrogen peroxide or serum depleted
medium.75 This study indicates that nuclear Rap1 responds to
oxidative stress in every cell type irrespective of telomerase
expression. The cytoplasmic pool of Rap1 remains constant
and seems likely to facilitate the preservation of cell survival
signaling NFkB pathway. One possible explanation is that
under oxidative conditions, nuclear Rap1 translocates to the
cytoplasm to maintain constant levels of Rap1 for continuous
signaling of NFkB (Fig. 2).
Potential role of Rap1 in diabetic cardiomyopathy
From a clinical standpoint, an inverse relationship exists
between leukocyte telomere length and chronological age.
Genetic variation and sex have an additional influence on accel-
erated leukocyte telomere shortening.76 Furthermore, substan-
tial evidence has demonstrated that telomere shortening has
been linked with greater risk of obesity77 and cardiovascular
disease.78 In particular, a cohort study conducted on 7,008 U.S.
residents suggested that a unit increase in percent body fat,
waist circumference (cm) and body mass index (kg/m2) con-
tributed, respectively, to a 0.01%, 0.09% and 0.2% decrease in
leukocyte telomere length (T/S ratio), indicating that life course
adiposity dynamics are the determinant of telomere shorten-
ing.77 Also, the Strong Heart Family Study sheds light on the
potential role of leukocyte telomere length in the prediction of
adverse cardiovascular disease outcomes.78 It was observed that
longer leukocyte telomere length was significantly linked with
reduced arterial stiffness.78 In another observational cohort
study on 257 kidney donors for transplantation provides evi-
dence for the close association between shorter telomere length
in peripheral blood leukocytes and kidney tissues and intrare-
nal arteriosclerosis, independent of cardiovascular risk fac-
tors.79 Thus, collectively, based on the available literature, it can
be suggested that telomere attrition plays a central role in the
development of renovascular and cardiovascular diseases in
humans.
Diabetic cardiomyopathy is a heart muscle disorder associ-
ated with oxidative stress and inflammation in people with
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diabetes, which can lead to inability of the heart to circulate
blood through the body effectively. Moreover, it is also previ-
ously reported that telomere shortening is observed in cardio-
myopathy.80–83 As the review focuses on both the telomeric
and non-telomeric functions of Rap1 and its role in the regula-
tion of telomeric length, metabolism, oxidative stress and
inflammation, collectively it can be anticipated that Rap1 plays
an important role in the pathophysiology of diabetic cardiomy-
opathy either directly or indirectly which is yet to be explored.
Conclusion and future perspectives
During the past decade, substantial evidence has been accumu-
lated for non-telomeric role for Rap1 in the regulation of
inflammation, oxidative stress and metabolism. The greatest
challenge at present is to comprehend what the downstream
molecules are, that allow Rap1 to execute pleiotropic functions.
Remarkably, some protein targets like NFkB and PPARa have
emerged as immediate downstream effectors of Rap1 so far
from genetic studies. NFkB activation is detrimental by trigger-
ing chronic inflammation through elevation of cytokines lead-
ing to cell death, including cardiac cells.84 Indeed, persistent
activation of NFkB has been associated with myocardial IRI.85
Simultaneously, PPARa regulates cardiac energy metabolism
and various cell signaling pathways concerning cardiovascular
health and disease.86,87 Thus, a continuing need exists for get-
ting definitive evidence for the Rap1 role in the cardiovascular
physiology and its pathological diseases like myocardial infarc-
tion. It raises several immediate questions like whether Rap1
modulation exacerbates myocardial IRI? Does Rap1 contribute
to inflammation through NFkB signaling during myocardial
IRI? Whether Rap1 regulates cardiac energy metabolism
through regulation of PPARa transcription? The enigma of
Rap1 and its putative effects cannot be resolved by genetic stud-
ies only, but the development of suitable animal model systems
will help to decipher the potentiality of Rap1 as a drug target in
cardiac diseases. Thus, it is prime requisite to gain a compre-
hensive knowledge on the Rap1 regulatory role in the cardio-
vascular biology.
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